辉瑞：与三生制药完成授权协议，获创新癌症免疫疗法独家授权

Core Insights - Pfizer has completed a global exclusive licensing agreement with 3SBio for SSGJ-707, a dual-specific antibody targeting PD-1 and VEGF, enhancing Pfizer's oncology product line [1] Group 1 - The agreement allows Pfizer exclusive rights for the development, manufacturing, and commercialization of SSGJ-707 outside of China, where 3SBio retains the rights [1] - SSGJ-707 is developed based on 3SBio's proprietary CLF2 platform, indicating a focus on innovative cancer immunotherapy [1] - This partnership strengthens Pfizer's position in the oncology market, reflecting its commitment to expanding its cancer treatment portfolio [1]